Treatment of Vitiligo in Pediatric Patients

Introduction to Treatment Options

The British Journal of Dermatology recommends the use of topical calcineurin inhibitors, such as tacrolimus 0.1% or pimecrolimus 1%, as the first-line treatment for localized vitiligo in children, due to their superior safety profile and comparable efficacy to potent corticosteroids 1

The British Journal of Dermatology suggests documenting the extent of the disease with serial photographs to monitor the response to treatment every 2-3 months, allowing for objective assessment of treatment efficacy 2, 1
The American Academy of Pediatrics recommends performing thyroid function tests, including anti-thyroglobulin antibodies, before starting treatment, given the high prevalence of thyroid autoimmune diseases in patients with vitiligo 1, 3
Evaluating the skin phototype is crucial to guide therapeutic decisions, as certain treatments may be more suitable for specific skin types 2
A psychological evaluation of the child and parents should be conducted, as vitiligo can have a significant impact on the quality of life 4, 5

The British Journal of Dermatology recommends topical calcineurin inhibitors, such as tacrolimus 0.1% or pimecrolimus 1%, as the first-line treatment for localized vitiligo in children, with a response rate of 58% for facial lesions and 23-39% for non-facial lesions 1
Potent topical corticosteroids, such as clobetasol propionate 0.05% or betamethasone valerate 0.1%, can be used as an alternative for a trial period not exceeding 2 months, with a response rate of 15-25% and a risk of skin atrophy 2, 1

The British Journal of Dermatology recommends narrowband UVB phototherapy as a treatment option for children with extensive or refractory vitiligo, with a preference over PUVA due to its greater efficacy and safety 2
The treatment should be ideally reserved for patients with darker skin phototypes, and the cumulative dose should be limited to 200 treatments for skin phototypes I-III to minimize the risk of skin damage 2, 6

The British Journal of Dermatology suggests that psychological interventions should be offered to improve coping mechanisms in children with vitiligo, and that parents should receive psychological counseling to support their child's treatment 2, 5
Regular assessment of the psychological impact of the disease on the child and family is essential to provide adequate support and guidance 4, 5

The British Journal of Dermatology advises against prolonging the use of potent corticosteroids beyond 2 months to prevent skin atrophy, and against using systemic corticosteroids in children due to their unacceptable toxicity 2, 6
Surgical treatments are not recommended in pediatric patients due to the lack of evidence supporting their efficacy and safety 2, 4, 5

The British Journal of Dermatology recommends using standardized serial photographs to objectively evaluate the response to treatment, allowing for timely adjustments to the treatment plan 2, 1